Skip to content
TrialScanner

NCT02655822

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Phase 1CompletedCRVSLead

Registry record

Lead sponsor
Corvus Pharmaceuticals, Inc.
Conditions
Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer
Primary completion
Jun 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02655822 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02655822: Phase 1/1b Study to Evaluate... | TrialScanner